03.05.2016 21:15:00

Biogen Inc. -- Moody's: Biogen's hemophilia spin-off is credit negative

New York, May 03, 2016 -- Moody's Investors Service commented that the announcement by Biogen Inc. that it intends to spin-off its hemophilia business into an independent publicly traded company is credit negative. There is no impact on the company's Baa1 senior unsecured rating. The rating outlook remains negative.

Vollständigen Artikel bei Moodys lesen